Guadalupe Guzmán

Instituto de Medicina Tropical “Pedro Kourí”

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Laura Lazo

Centro de Ingeniería Genética y Biotecnología

Lisset Hermida

Zhejiang Yongning Pharma (China)

Gerardo Guillén

Centro de Ingeniería Genética y Biotecnología

Iris Valdés

Centro de Ingeniería Genética y Biotecnología

Lázaro Gil

Unity Health Toronto

Ernesto Marcos

Centro de Ingeniería Genética y Biotecnología

Susana Vázquez

Hospital del Mar Research Institute

D Eliana Icochea

National University of San Marcos

Verena Muzio

Centro de Ingeniería Genética y Biotecnología

Gabriel Márquez

Centro de Ingeniería Genética y Biotecnología

Cooperative Institutions

Instituto de Medicina Tropical “Pedro Kourí”

Centro de Ingeniería Genética y Biotecnología

Wadsworth Center

Administración Nacional de Laboratorios e Institutos de Salud

Instituto Evandro Chagas

Secretaria de Salud

Instituto Conmemorativo Gorgas de Estudios de la Salud

Centers for Disease Control and Prevention

Faculdade de Medicina de São José do Rio Preto

National Center for Genetic Engineering and Biotechnology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

PREVALENCIA DE ANTICUERPOS CONTRA PARAMYXOVIRUS AVIAR TIPO 1 EN PAVOS DE CRIANZA FAMILIAR EN CUATRO PROVINCIAS DE LIMA, PERÚ PREVALENCE OF ANTIBODIES AGAINST AVIAN PARAMYXOVIRUS TYPE 1 IN BACKYARD TURKEYS IN FOUR PROVINCES OF LIMA, PERU

Franklin Santa John Cruz D Eliana Icochea Guadalupe Guzmán Alberto Manchego S.

The objective of the study was to determine the prevalence of antibodies against avian Paramyxovirus type 1 (APMV-1) in backyard turkeys (n=388) in four provinces of Lima, Peru (Lima, Huaral, Huaura, and Barranca). Blood samples were collected from August to December 2008 and analyzed by hemagglutination inhibition test. The resulting seroprevalence was 3.9% as 15/388 turkeys showed antibody titers consistent with a viral challenge of APMV-1. The highest frequency of positive samples (10/15) was

Seroprevalence

Newcastle Disease

Source

Cite

Citations (0)

Development of a Monoclonal Antibody Specific to a Recombinant Envelope Protein from Dengue Virus Type 4 Expressed inPichia pastoris

Hybridoma (2001)

Maritza Pupo-Antúnez Rayner Rodrı́guez Mayling Álvarez Nevys Amin Hermis Rodríguez

A mouse monoclonal antibody (MAb, 4B6) was able to recognize dengue virus type 4 envelope (E) protein both as a recombinant protein in Pichia pastoris and when it was present in infected brains of suckling mice. 4B6 was characterized by enzyme-linked immunoadsorbent assay (ELISA), hemaglutination inhibition, neutralization, and immunoblot. The MAb was isotyped as IgG2a. It was serotype 4 specific and it inhibited hemaglutination and neutralized homologous virus. It did not enhance infection of P338D1 cells by dengue type 4 virus strain H-241 strain. This MAb was reactive with recombinant E protein and dengue 4 virus, as revealed by Western blot. In vivo, MAb 4B6 conferred passive protection in mice challenged with homologous virus. Currently, this MAb is being used to purify recombinant E protein for further studies.

Flavivirus

10.1089/027245701300060409

Cite

Citations (11)

A recombinant envelope protein from Dengue virus purified by IMAC is bioequivalent with its immune-affinity chromatography purified counterpart

Journal of Biotechnology (2002)

Lisset Hermida Rafael Rodríguez Laura Lazo Carlos López Gabriel Márquez

Ion chromatography

10.1016/s0168-1656(01)00406-0

Cite

Citations (18)

Sequence analysis of Coxsackie A9 viruses isolated during 1990-1993 in Cuba from patients with meningitis, myocarditis and epidemic neuropathy

Biotecnología aplicada (1994)

Eileen Riego Miguel Marrero Eric Calvo Ricardo Bringas M.J. López Álvarez

Sequence (biology)

Source

Cite

Citations (4)

Comparison of the productive performance in broilers supplemented with probiotic or antibiotic

Revista de Investigaciones Veterinarias del Perú (2010)

P. Carlos Osorio D Eliana Icochea S Pablo Reyna Guadalupe Guzmán M. Fernando Cazorla

Source

Cite

Citations (0)

Recommendations for Laboratory Detection and Diagnosis of Arbovirus Infections in the Region of the Americas

Pan American Health Organization eBooks (2023)

Laura D. Kramer Marcela Cintia Victoria Fabbri Alejandra Morales Guadalupe Guzmán

Human infection with arboviruses, such as dengue, yellow fever, chikungunya and zika, occurs through the bite of blood-sucking arthropods (mosquitos, ticks and midges, among others). There are more than 100 types of arboviruses and the infections they trigger range in severity from asymptomatic to life-threatening. In addition, constant evolution of many of these viruses have generated different genotypes and viral variants that migth eventually impact the public health systems. Outbreaks caused by these viruses are increasingly common throughout tropical and sub-tropical regions, including much of the Americas, making them an issue of international concern. According to the World Health Organization, almost 4 billion people live in areas where arboviruses are current public health threats. This publication provides technical recommendations for public health laboratories involved in arbovirus diagnostic and surveillance. It covers the types of specimens most useful for diagnosing infections; lists minimum clinical datasets for sample labelling and analysis; and describes best practices for processing and handling of samples, along with recommended workflows and biosafety considerations. The most appropriate tests for each of the most common arboviruses are presented with recommended diagnostic algorithms. Both direct diagnostic methods – through genome detection, antigen detection and viral isolation – and indirect serological methods (which detect the immune response to viral infection rather than the virus itself) are included. In addition to its primary target audience of public health laboratory staff, this publication will be also useful to research centers that identify arboviral infections as part of their research.

Arbovirus Infections

Zika Virus

Biosafety

Public health surveillance

10.37774/9789275125878

Cite

Citations (1)

UltramicroELISA de captura para la detección de anticuerpos IgG al dengue (UMELISA-DENGUE IgG).

DOAJ (DOAJ: Directory of Open Access Journals) (2003)

Carmen Rodríguez Acosta Regla Herrera Raquel López Susana Vázquez Guadalupe Guzmán

Resumen es: En este trabajo se presentan los resultados de la estandarizacion y evaluacion del ultramicroELISA Dengue IgG (UMELISA DENGUE IgG). Con este fin se estud...

Source

Cite

Citations (0)

Characterization of a new polyvalent antivenom (Antivipmyn® Africa) against African vipers and elapids

Toxicon (2008)

Blanca Ramos‐Cerrillo Adolfo Rafael de Roodt Jean‐Philippe Chippaux Laura Olguín Andrea Casasola

Antivenom

Economic shortage

10.1016/j.toxicon.2008.09.002

Cite

Citations (80)

Virus-like particles as nanovaccine candidates

Advances in Natural Sciences Nanoscience and Nanotechnology (2013)

Gerardo Guillén Julio Aguilar Santiago Dueñas Lisset Hermida Enrique V. Iglesias

The existing vaccines are mainly limited to the microorganisms we are able to culture and produce and/or to those whose killing is mediated by humoral response (antibody mediated). It has been more difficult to develop vaccines capable of inducing a functional cellular response needed to prevent or cure chronic diseases. New strategies should be taken into account in the improvement of cell-based immune responses in order to prevent and control the infections and eventually clear the virus. Preclinical and clinical results with vaccine candidates developed as a vaccine platform based on virus-like particles (VLPs) evidenced their ability to stimulate mucosal as well as systemic immunity. Particles based on envelope, membrane or nucleocapsid microbial proteins induce a strong immune response after nasal or parenteral administration in mice, non-human primates and humans. In addition, the immune response obtained was modulated in a Th1 sense. The VLPs were also able to immunoenhance the humoral and cellular immune responses against several viral pathogens. Studies in animals and humans with nasal and systemic formulations evidenced that it is possible to induce functional immune response against HBV, HCV, HIV and dengue virus.

Humoral immunity

10.1088/2043-6262/4/1/015005

Cite

Citations (6)

Development of a technological framework for using virus-like particles as adjuvants in prophylactic and therapeutic vaccines: demonstration of effect in animal models and humans

Biotecnología aplicada (2011)

Gerardo Guillén Julio Aguilar Santiago Dueñas Lisset Hermida Enrique V. Iglesias

Developing an effective vaccine entails: 1) proper antigenic presentation to the immune system, inducing a response of adequate intensity 2) a long duration for said response 3) the ability to steer this response towards the immune system pattern most suited for the elimination of the pathogen. Among the current crop of adjuvants, only aluminum-based gels and some oil emulsions are compliant with established regulatory and safety requirements and, not surprisingly, have received extensive use. The present work describes the development of a technological framework for the inclusion of virus-like particles (VLP) as adjuvants in vaccine preparations, allowing the induction of a functional immune response in humans that achieves seroconversion and protective antibody levels without the need for additional adjuvants. This technological framework comprises both the production and formulation of antigens as virus-like particles and the use of these VLP as adjuvants for soluble antigens, obtaining high levels of induction of the Th1 cell response which, in combination with the humoral response, have been shown to confer a fully functional immunoprotective status in animal models. Some of the novel aspects of the present work are the development of a common methodology for the obtention and formulation of different VLP; the demonstration that VLP-containing formulations are able to bias response towards a Th1 pattern; the finding that VLP can be used as adjuvants stimulating a fully functional response in humans to soluble antigens; the safety of VLP-adjuvanted formulations and, lastly, the induction of a functional, protective response in animal models and humans

Antibody response

Seroconversion

Source

Cite

Citations (0)